Section: 8. Immunomodulators and antineoplastics  ➤  8.2. Antineoplastics and supportive medicines  ➤  8.2.1. Cytotoxic medicines

### Bendamustine

**Indication**
Chronic lymphocytic leukaemia or small lymphocytic lymphoma

**INN**
Bendamustine

**Medicine type**
Chemical agent

**List type**
Complementary

**Formulations**
Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL

**EML status history**
First added in 2015 (TRS 994)

**Sex**
All

**Age**
Adolescents and adults

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit [www.MedsPal.org](http://www.MedsPal.org). Read more about patents.

**Tags**
Cancer

**Wikipedia**
Bendamustine

**DrugBank**
Bendamustine

---

**Summary of evidence and Expert Committee recommendations**

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, bendamustine was added to the complementary list of the EML for use in treatment protocols for chronic lymphocytic leukaemia. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for chronic lymphocytic leukaemia is attached.